2007
Fibroblast Growth Factors
Murakami M, Elfenbein A, Simons M. Fibroblast Growth Factors. 2007, 291-303. DOI: 10.1017/cbo9780511546198.035.Peer-Reviewed Original ResearchFGF genesFibroblast growth factorGene duplicationGrowth factorBovine brainFGF receptor genesBasic isoelectric pointBALB/c 3T3 fibroblast cellsEarly vertebratesCaenorhabditis elegansDrosophila melanogasterFruit flyFGFR genesBasic fibroblast growth factorAcidic fibroblast growth factorGenesHeparin-Sepharose chromatographyReceptor geneProteinNomenclature CommitteeSepharose chromatographyFibroblast cellsBasic proteinMyelin basic proteinDuplication
2000
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study
Laham R, Chronos N, Pike M, Leimbach M, Udelson J, Pearlman J, Pettigrew R, Whitehouse MJ, Yoshizawa C, Simons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. Journal Of The American College Of Cardiology 2000, 36: 2132-2139. PMID: 11127452, DOI: 10.1016/s0735-1097(00)00988-8.Peer-Reviewed Original ResearchConceptsIntracoronary basic fibroblast growth factorOpen-label dose-escalation studyDose-escalation studyIschemic heart diseaseBasic fibroblast growth factorFibroblast growth factorHeart diseaseGrowth factorPhase I open-label dose-escalation studyFGF-2Non-Q-wave myocardial infarctionSevere ischemic heart diseaseSeattle Angina QuestionnaireTreadmill exercise testingQuality of lifeRegional wall thickeningMagnetic resonance imagingRFGF-2Angina QuestionnaireExercise toleranceRetinal examinationEscalation studyExercise testingIntracoronary administrationLaboratory parametersBasic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts
Hampton T, Amende I, Fong J, Laubach V, Li J, Metais C, Simons M. Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts. AJP Heart And Circulatory Physiology 2000, 279: h260-h268. PMID: 10899065, DOI: 10.1152/ajpheart.2000.279.1.h260.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCalciumCoronary VesselsEnzyme InhibitorsFemaleFibroblast Growth Factor 2HeartIn Vitro TechniquesLysineMaleMiceMice, Inbred C57BLMice, KnockoutMyocardial IschemiaMyocardial ReperfusionMyocardial StunningNG-Nitroarginine Methyl EsterNitric Oxide SynthaseNitric Oxide Synthase Type IIRecombinant ProteinsConceptsFGF-2Mouse heartsBasic FGFIschemia-reperfusion injuryExpression of NOS2Onset of ischemiaInducible NO synthaseBasic fibroblast growth factorNitric oxide productionNO-selective electrodeFibroblast growth factorLV dysfunctionIschemic contractureVentricular functionLV recoveryNO synthaseIntracellular calciumProtective effectTransgenic heartsOxide productionIschemiaGrowth factorReperfusionSelective inhibitorVehicle controlTherapeutic Angiogenesis
Simons M, Laham R, Post M, Sellke F. Therapeutic Angiogenesis. BioDrugs 2000, 14: 13-20. PMID: 18034552, DOI: 10.2165/00063030-200014010-00002.Peer-Reviewed Original ResearchGrowth factorTherapeutic angiogenesisAdvanced coronary diseaseAdverse effect profileInitial clinical dataRecent clinical experienceBasic fibroblast growth factorQuality of lifeAngiogenic growth factorsFibroblast growth factorCoronary diseaseEffect profileClinical dataPreclinical studiesAnimal modelsClinical experienceNew vasculatureClinical applicationPractical clinical applicationsAngiogenesisBFGFBasic biologyPatientsFactorsSymptoms
1999
Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery
Laham R, Sellke F, Edelman E, Pearlman J, Ware J, Brown D, Gold J, Simons M. Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery. Circulation 1999, 100: 1865-1871. PMID: 10545430, DOI: 10.1161/01.cir.100.18.1865.Peer-Reviewed Original ResearchMeSH KeywordsAlginatesCoronary Artery BypassCoronary VesselsDelayed-Action PreparationsDouble-Blind MethodDrug CarriersDrug CompoundingDrug ImplantsFemaleFibroblast Growth Factor 2Follow-Up StudiesGlucuronic AcidHeparinHexuronic AcidsHumansMaleMiddle AgedPatient SelectionPlacebosRecombinant ProteinsConceptsBasic fibroblast growth factorBFGF groupFibroblast growth factorTreatment-related adverse eventsQ-wave myocardial infarctionGrowth factorLocal perivascular deliverySerum bFGF levelsPlacebo-controlled studyCoronary bypass surgerySubset of patientsMode of therapyMagnetic resonance assessmentPromising treatment strategyNuclear perfusionOperative deathsRecurrent anginaStandard revascularizationNew blood vesselsPlacebo groupRepeat revascularizationAdverse eventsBypass surgeryControl patientsPerivascular deliveryTherapeutic Angiogenesis Using Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Using Various Delivery Strategies.
Laham R, Garcia L, Baim D, Post M, Simons M. Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Using Various Delivery Strategies. Current Interventional Cardiology Reports 1999, 1: 228-233. PMID: 11096629.Peer-Reviewed Original ResearchVascular endothelial growth factorBasic fibroblast growth factorEndothelial growth factorGrowth factorFibroblast growth factorDouble-blind placebo-controlled trialIntravenous deliveryTherapeutic angiogenesisStandard revascularization proceduresPlacebo-controlled trialLarger patient populationChronic myocardial ischemiaDelivery strategiesPerivascular deliveryRevascularization proceduresPatient populationAtrial injectionIntrapericardial administrationTreatment modalitiesMyocardial ischemiaSustained administrationTreatment strategiesClinical studiesOutcome measuresIntramyocardial administrationThe Role of Syndecan Cytoplasmic Domain in Basic Fibroblast Growth Factor-dependent Signal Transduction*
Volk R, Schwartz J, Li J, Rosenberg R, Simons M. The Role of Syndecan Cytoplasmic Domain in Basic Fibroblast Growth Factor-dependent Signal Transduction*. Journal Of Biological Chemistry 1999, 274: 24417-24424. PMID: 10446222, DOI: 10.1074/jbc.274.34.24417.Peer-Reviewed Original ResearchConceptsCytoplasmic domainBasic fibroblast growth factorSyndecan-4Ectoplasmic domainSignal transductionSyndecan-4 cytoplasmic domainVector-transduced cellsSyndecan cytoplasmic domainsGrowth factor-dependent signal transductionHeparan sulfate attachment sitesTransmembrane/cytoplasmic domainsGlycosylphosphatidylinositol (GPI) anchor sequenceImmortalized human cellsGlypican-1Full-length sequencesAddition of bFGFCytoplasmic tailAnchor sequenceChimeric proteinMigration of cellsFibroblast growth factorLow-serum mediumHuman cellsGrowth assaysVC cells
1998
Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results
Sellke F, Laham R, Edelman E, Pearlman J, Simons M. Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results. The Annals Of Thoracic Surgery 1998, 65: 1540-1544. PMID: 9647055, DOI: 10.1016/s0003-4975(98)00340-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlginatesAngina PectorisCollateral CirculationCoronary Artery BypassCoronary Artery DiseaseCoronary CirculationCoronary VesselsCreatinineDelayed-Action PreparationsDrug CarriersFeasibility StudiesFemaleFibroblast Growth Factor 2Follow-Up StudiesGlucuronic AcidHeparinHexuronic AcidsHumansMaleMiddle AgedMyocardial ContractionMyocardial InfarctionNeovascularization, PhysiologicPericardiumSafetyStroke VolumeSurvival RateConceptsBasic fibroblast growth factorCoronary artery bypassFibroblast growth factorArtery bypassGrowth factorTherapeutic angiogenesisConventional coronary artery bypassBasic fibroblast growth factor (bFGF) administrationSlow-release devicesStress perfusion scansPerioperative myocardial infarctionSerum creatinine levelsDifficult clinical problemFixed perfusion defectsLong-term resultsMyocardial contractile functionGrowth factor administrationOperative mortalityPatent arteriesMyocardial revascularizationCreatinine levelsEjection fractionClinical efficacyHepatic toxicityPerfusion scanRegulation of Syndecan-4 Phosphorylation in Vivo *
Horowitz A, Simons M. Regulation of Syndecan-4 Phosphorylation in Vivo *. Journal Of Biological Chemistry 1998, 273: 10914-10918. PMID: 9556568, DOI: 10.1074/jbc.273.18.10914.Peer-Reviewed Original ResearchConceptsCytoplasmic tailNovel PKC isozymesSyndecan-4Basic fibroblast growth factorProtein serine/threonine phosphatase type 1Serine/threonine phosphatasePKC isozymesSingle serine residuePhosphatase type 1Phosphatase inhibitor calyculinProtein kinase CNIH 3T3 fibroblastsThreonine phosphataseVivo phosphorylationEffects of bFGFSerine residuesTransmembrane proteoglycansConventional PKCFibroblast growth factorKinase CPhosphorylationPKC inhibitorPotential involvementGrowth factorIsozymes
1996
Local Extravascular Growth Factor Delivery in Myocardial Ischemia
Lopez J, Simons M. Local Extravascular Growth Factor Delivery in Myocardial Ischemia. Drug Delivery 1996, 3: 143-147. PMID: 26790909, DOI: 10.3109/10717549609029443.Peer-Reviewed Original ResearchBasic fibroblast growth factorVascular endothelial growth factorIschemic myocardiumGrowth factorCoronary collateral circulationNumber of microvesselsNon-ischemic myocardiumImplantable osmotic pumpMyocardial blood flowPerivascular drug deliveryEndothelial growth factorAngiogenic growth factorsFibroblast growth factorCollateral circulationChronic ischemiaMyocardial performanceMyocardial ischemiaVEGF administrationHeart sectionsBlood flowControl animalsMyocardial perfusionOsmotic pumpControl groupExogenous growth factor delivery